• 主页
  • 查找结果
  • Assessment of diagnostic and therapeutic approaches of Helicobacter pylori-associated iron deficiency and anemia in children with dyspeptic symptoms.

Assessment of diagnostic and therapeutic approaches of Helicobacter pylori-associated iron deficiency and anemia in children with dyspeptic symptoms.

Journal of the Egyptian Society of Parasitology (2015-02-04)
Mohiee El-Deen El-Aziz Awad, Saleh Mohamed Amin, Saied Mohamed Abdou
摘要

This study assessed the diagnostic approaches of Helicobacter pylori (IP)-associated iron deficiency (ID) and anemia (IDA) in children with dyspeptic symptoms and evaluated the effect of simultaneous anti-H. pylori (anti-HIP) therapy and oral iron in comparison with each of anti? HP therapy and oral iron therapy alone, on iron status as assessed by serum soluble transferrin receptor (sTfR) level. Two hundreds children with dyspeptic symptoms were subjected to clinical evaluation, stool examination, CBC, biochemical assays for serum iron parameters and measurements of serum IgG antibodies to HP and serum sTfR level by ELISA. Sixty children were found to have HP. associated ID or IDA and were randomly divided into 3 groups (20 children each). GA received 2-week anti-HP therapy plus 90-day oral iron, and GB received 2-week anti-HP therapy alone whereas group C received 90-day oral iron alone. Re-evaluation of the 3 groups was performed after 3 months of treatment initiation by repeat CBC and serum sTfR level. Children (45%) were HP-seropositive. The mean values of serum sTfR were significantly higher in HP-positive group and in HP-positive children with IDA than in HP-negative group and in HP-negative children with IDA although no significant differences were noted in hematologic variables and iron parameters between the corresponding groups and children. As regard treatment groups, there were significant improvements in the mean values of indices of IDA status (HIb, MCH, MCV, sTfR) and ID status (sTtRi) at 3 months of treatment initiation compared with their baseline values after. anti-HP triple therapy either with oral iron or without oral iron whereas the control children who were treated with oral iron alone showed insignificant changes despite oral iron administration. The improvements in these parameters were significantly greater in groups of children who received anti-HP therapy either combined with iron or alone, where compared with those who did not receive anti-HP therapy. Their magnitudes were significantly higher among children receiving anti-HP therapy combined with oral iron when compared with that receiving anti-HP therapy alone.

材料
货号
品牌
产品描述

Sigma-Aldrich
铁, ≥99%, reduced, powder (fine)
Sigma-Aldrich
铁蛋白 来源于马脾脏, Type I, saline solution
Sigma-Aldrich
铁, powder, −325 mesh, 97%
Sigma-Aldrich
羰基铁, ≥97% Fe basis
Sigma-Aldrich
铁, powder, <10 μm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, puriss. p.a., carbonyl-Iron powder, low in magnesium and manganese compounds, ≥99.5% (RT)
Sigma-Aldrich
铁, flakes, ≥99.99% trace metals basis
Sigma-Aldrich
铁, nanopowder, 35-45 nm particle size, 99.5% trace metals basis
Sigma-Aldrich
铁, granular, 10-40 mesh, >99.99% trace metals basis
Sigma-Aldrich
铁, chips, 99.98% trace metals basis
Sigma-Aldrich
铁, foil, thickness 0.1 mm, ≥99.9% trace metals basis
Sigma-Aldrich
铁蛋白 来源于人类肝脏, Type IV, 10 μg/mL
Sigma-Aldrich
铁, foil, thickness 0.25 mm, ≥99.99% trace metals basis
Sigma-Aldrich
铁蛋白 来源于人类脾脏, Type V, 10 μg/mL in 0.15 M NaCl, 10 mM Tris, pH 8.0, containing 0.1% sodium azide
Sigma-Aldrich
铁, wire, diam. 1.0 mm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, carbon coated magnetic, nanopowder, 25 nm avg. part. size, 99.5% trace metals basis
Sigma-Aldrich
铁, wire, diam. 0.5 mm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, rod, diam. 6.3 mm, 99.98% trace metals basis
铁, IRMM®, certified reference material, 0.5 mm wire
铁, foil, 300x300mm, thickness 0.1mm, hard, 99.5%
铁, foil, 0.2m coil, thickness 0.5mm, coil width 49mm, armco« soft ingot 99.8+%
铁, wire reel, 1m, diameter 0.025mm, as drawn, 99.99+%
铁, wire reel, 20m, diameter 0.125mm, hard, 99.5%
铁, foil, 10mm disks, thickness 0.01mm, 99.85%
铁, foil, 10mm disks, thickness 0.01mm, 99.99+%
铁, foil, 10mm disks, thickness 0.020mm, 99.85%
铁, foil, 10mm disks, thickness 0.025mm, as rolled, 99.99+%
铁, foil, 10mm disks, thickness 0.025mm, hard, 99.5%
铁, foil, 10mm disks, thickness 0.038mm, hard, 99.5%
铁, foil, 10mm disks, thickness 0.05mm, as rolled, 99.99+%

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。